Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.
Antares Therapeutics on Wednesday entered into a strategic collaboration with Novartis AG (NYSE:NVS) aimed at discovering, developing, and commercializing small-molecule therapies targeting historically difficult-to-drug cancer targets.
The agreement could generate up to $1.9 billion for Antares, including upfront and milestone payments.
Read Next
Biotech
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with…
Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and…
Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as sales for cancer drugs…
Novartis inks second molecular glue deal with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones across…
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything…
